Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · IEX Real-Time Price · USD
15.06
-0.29 (-1.89%)
At close: May 6, 2024, 4:00 PM
14.78
-0.28 (-1.86%)
After-hours: May 6, 2024, 5:57 PM EDT
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
150
Market Cap
1.20B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 33.19M | 14.38M | 76.41% |
Dec 31, 2021 | 18.82M | 3.41M | 22.16% |
Dec 31, 2020 | 15.40M | -5.09M | -24.83% |
Dec 31, 2019 | 20.49M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 379.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pacira BioSciences | 674.98M |
Collegium Pharmaceutical | 566.77M |
BioCryst Pharmaceuticals | 331.41M |
Maravai LifeSciences Holdings | 288.95M |
MannKind | 198.96M |
Immatics | 60.00M |
AbCellera Biologics | 38.03M |
SRRK News
- 24 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress - Business Wire
- 2 months ago - Scholar Rock to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer - Business Wire
- 3 months ago - Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management - Business Wire
- 3 months ago - Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia - Business Wire
- 3 months ago - Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity - Business Wire
- 4 months ago - Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 - Business Wire